Sarepta Soars After FDA Staffer’s Exit Lifts Approval Hopes
- Ron Farkas, reviewer critical of Sarepta drug, departed
- Sarepta still awaits FDA decision on muscle disease treatment
This article is for subscribers only.
Sarepta Therapeutics Inc. rose the most since June after a U.S. Food and Drug Administration reviewer who was critical of the drugmaker’s proposed treatment left the agency, potentially brightening prospects for approval of the medicine.
Ron Farkas is no longer at the FDA, according to an e-mail on Wednesday from Sandy Walsh, a spokeswoman. Farkas led a review that criticized studies of Sarepta’s drug, called eteplirsen, that was developed to treat a lethal muscle disease. He started working at Parexel International Corp., a consulting firm, earlier this month, according to spokeswoman Cristi Barnett.